Efficacy and Safety of Paliperidone ER in First Episode Psychosis
NCT01157585 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75
Last updated 2015-07-31
Summary
The aim of the study is to investigate the efficacy and safety of Paliperidone ER in patients with first episode psychosis.
Conditions
- First Episode Psychosis
Interventions
- DRUG
-
paliperidone ER
8 week prospective study
Sponsors & Collaborators
-
Janssen Korea, Ltd., Korea
collaborator INDUSTRY -
Chonbuk National University Hospital
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 59 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-02-28
- Primary Completion
- 2013-02-28
- Completion
- 2013-02-28
Countries
- South Korea
Study Locations
More Related Trials
-
An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
NCT01299389 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety With Ziprasidone in First-episode Psychosis
NCT01157559 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants
NCT00784238 ·Status: COMPLETED ·Phase: PHASE4
-
Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia
NCT00827840 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Aripiprazole in First Episode Psychosis
NCT01026584 ·Status: COMPLETED ·Phase: PHASE4
-
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
NCT00488319 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia
NCT01541371 ·Status: COMPLETED ·Phase: PHASE3
-
Paliperidone Palmitate Flexible Dosing in Schizophrenia
NCT01281527 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia
NCT01577160 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia
NCT01662648 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia
NCT01051531 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
NCT00460512 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone
NCT01010776 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia
NCT01662310 ·Status: COMPLETED ·Phase: PHASE3
-
Different Safety Profile of Risperidone and Paliperidone Extended-release
NCT01284959 ·Status: COMPLETED ·Phase: PHASE4
-
Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia
NCT00085748 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics
NCT01685931 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia
NCT00566631 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia
NCT00524043 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
NCT01009047 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.
NCT00086320 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
NCT02713282 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
NCT00397033 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia
NCT01150448 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia
NCT00334126 ·Status: COMPLETED ·Phase: PHASE3